Issue 2/2020
Content (18 Articles)
Learnings for Health Economics from the Early Stages of the COVID-19 Pandemic
Anthony J. Hatswell
Group Testing for SARS-CoV-2: Forward to the Past?
Koen B. Pouwels, Laurence S. J. Roope, Adrian Barnett, David J. Hunter, Terry M. Nolan, Philip M. Clarke
A Systematic Review of Model-Based Economic Evaluations of Treatments for Venous Leg Ulcers
Ashley Layer, Emma McManus, N. J. Levell
Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review
T. I. Armina Padmasawitri, Sarah Maria Saragih, Gerardus W. Frederix, Olaf Klungel, Anke M. Hövels
Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
Herbert H. Loong, Carlos K. H. Wong, Linda Kam Suet Leung, Praveen Dhankhar, Ralph P. Insinga, Sheenu Chandwani, Danny C. Hsu, Mary Y. K. Lee, Min Huang, James Pellissier, Akanksha Rai, Monika Achra, Seng Chuen Tan
Cost of Delivering Secondary Healthcare Through the Public Sector in India
Shankar Prinja, Akashdeep Singh Chauhan, Pankaj Bahuguna, Sakhtivel Selvaraj, V. R. Muraleedharan, Thiagarajan Sundararaman
Touch for Health: Use of Pavlovian Processes with Physical Touch as a Means to Improve Menstrual Hygiene Management Initiatives, Measured by Willingness to Pay
Siobhan K. Yilmaz, Alok K. Bohara, Soumi Roy Chowdhury
Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
Margarita Capel, Andreea Ciudin, María Mareque, Raquel María Rodríguez-Rincón, Susana Simón, Itziar Oyagüez
Health Technology Assessment of Drugs in Ireland: An Analysis of Timelines
Emma Connolly, Helen O’Donnell, Felicity Lamrock, Lesley Tilson, Michael Barry
Economic Evaluation of Azacitidine in Elderly Patients with Acute Myeloid Leukemia with High Blast Counts
D. Coyle, Pierre J. A. Villeneuve
Ticagrelor Removal by CytoSorb® in Patients Requiring Emergent or Urgent Cardiac Surgery: A UK-Based Cost-Utility Analysis
Mehdi Javanbakht, Miranda Trevor, Mohsen Rezaei Hemami, Kazem Rahimi, Michael Branagan-Harris, Fabian Degener, Daniel Adam, Franziska Preissing, Jörg Scheier, Suzanne F. Cook, Eric Mortensen
Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands
Judith J. Gout-Zwart, Lisa A. de Jong, Lisanne Saptenno, Maarten J. Postma
Impact of a Clinical Pharmacist Intervention on Medicine Costs in Patients with Chronic Obstructive Pulmonary Disease in India
Suhaj Abdulsalim, Mazhuvancherry Kesavan Unnikrishnan, Mohan K. Manu, Saud Alsahali, Alian A. Alrasheedy, Antony P. Martin, Brian Godman, Abubakr A. Alfadl
Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection
Rachael Batteson, Rose Hart, Matthew Hemstock, Kyna Gooden, Srividya Kotapati, Stephane Roze, Dawn Lee, Adenike Amadi
The Costs of Industry-Sponsored Drug Trials in Canada
Dat T. Tran, Ilke Akpinar, Philip Jacobs
A Nationwide Study of Prevalence Rates and Characteristics of 199 Chronic Conditions in Denmark
Michael Falk Hvidberg, Soeren Paaske Johnsen, Michael Davidsen, Lars Ehlers
Treatment Patterns and Costs Associated with Stage IV Non-Small Cell Lung Cancer in a Mexican Population: A Chart Review
Jorge Arturo Alatorre, Saúl Campos-Gómez, Emmanuel De la Mora, Diego Novick, Angélica Cruz, Jimena María Iglesias-Chiesa
Out-of-Pocket Cancer Care Costs and Value Frameworks: A Case Study in a Community Oncology Practice with a Financial Navigator Program
Christine Leopold, Carina Araujo-Lane, Carol Rosenberg, Melissa Gilkey, Anita K. Wagner